Search Results

AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease (PD).

Agreement focused on advancing Mitokinin’s PINK1 activator program for the potential treatment of Parkinson’s disease

The first two weeks of October saw BMS’s $4.8 billion buyout of Mirati, Lilly’s $1.4 billion purchase of Point, Kyowa Kirin’s $387 million acquisition of Orchard and AbbVie’s $110 million Mitokinin deal.

AbbVie bought an exclusive right to acquire San Francisco-based Mitokinin after the company completes its Investigational New Drug-enabling studies on its lead program, PINK1, for Parkinson’s disease.

The Japanese biotechnology and food company has bought into the gene therapy space with its $620 million acquisition of Ohio-based CDMO and clinical-stage biotech Forge Biologics.

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.

RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced the appointment of three external directors to its board of directors, Renee Ryan, Rana Al-Hallaq, Ph.D., and Alice Schroeder

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer Steven Engle will present at the Mitochondria-Targeted Drug Development Summit being held virtually on April 27 - 29, 2021.

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.

Advisors include accomplished research executives and thought leaders in fields of cardiovascular and precision medicine, genomics, and biopharmaceuticals